Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 10, No 3 (2017) Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia Abstract  similar documents
E. V. Ivanova, K. Z. Bachtiyarova
"... 428,222,026.35 rubles per year, mostly due to direct medical costs; of those, almost 50% is spent ..."
 
Vol 10, No 3 (2017) оценка экономического ущерба от рассеянного склероза в г. Уфа. Abstract  similar documents
,
"...   рассеянного склероза в городе Уфа  экономика России  только за год теряет 428222026,35 руб., при этом основную ..."
 
Vol 5, No 3 (2012) DEVELOPMENT OF A COMPUTER MODULE FOR FORECASTING AND ESTIMATING EFFICIENCY OF BASIC THERAPY OF MULTIPLE SCLEROSIS Abstract  similar documents
F. A. Khabirov, D. Kh. Shakirova, O. A. Dun, T. I. Khaibullin
"... рассеянного склероза, учитывающие индивидуальные особенности каждого больного. ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... показателей препарата окрелизумаб (Окревус®) в терапии рецидивирующих форм рассеянного склероза (РРС) у ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... orphan diseases were 15.73 bln rubles per year (6.36 bln rubles for children and 9.37 bln rubles ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... .64, 2.65, 4.74 million rubles in the first, second and third year respectively. Scenario 3 ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... approval process. Results. The average medical cost (per year) for nilotinib (1 683 thousand rubles or US ..."
 
Vol 5, No 2 (2012) THE ANALYSIS OF COST OF ILLNESS OF PREGNANT WOMEN WITH SYPHILIS Abstract  similar documents
A. I. Ovod, M. D. Mukovnina
"... лечение беременных женщин, больных сифилисом, а также членов их семей осуществляется за счет ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... ®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles ..."
 
Vol 5, No 2 (2012) VI Конгресс с международным участием «Развитие фармакоэкономики и фармакоэпидемиологии в Российской Федерации» Abstract  similar documents
"... - мен опытом; • Фармакоэкономика высокозатратных нозологий: рассеян- ный склероз; • Фармакоэкономика ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... терапии, а Велкейда – в третьей составили 468 110,84 и 498 771,21 руб. в первом и во втором сценариях ..."
 
Vol 12, No 2 (2019) Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Abstract  similar documents
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... with ceftazidime + avibactam amounted to 228.3 thousand rubles, which was lower than the cost of using ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov
"... combined drug is cost saving alternative that annually requires 22,000 rubles per patient, which is 2 ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... per patient medication costs of using regorafenib are 255,000 rubles, which is 104,000 rubles less ..."
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... .14 rubles, respectively). The cost per averted case of NE was 21 115 rubles within 35 days that is less than ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment Abstract  similar documents
A. U. Kulikov, V. V. Babiy
"... на территории РФ больные СД составляют порядка 5-7% населения и с каждым годом их численность ..."
 
Vol 9, No 3 (2016) DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY Abstract  similar documents
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov
"... Цель исследования – анализ реальной практики лекарственного обеспечения больных раком молочной ..."
 
Vol 8, No 4 (2015) ABC-, VEN- AND FREQUENCY ANALYSIS OF TREATMENT OF ATRIAL FIBRILLATION IN OUTCOME PATIENTS Abstract  similar documents
A. N. Korobeynikova, S. V. Malchikova
"... . For the treatment of patient with atrial fibrillation it spends an average of 11245.2 rubles per patient ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... for Sumamed (Teva), and it amounted to 39 367.50 rubles. Sumamed was characterized by the highest clinical ..."
 
Vol 11, No 1 (2018) Antimicrobial therapy of community-acquired pneumonia in a hospital setting (clinical and economic aspects) Abstract  similar documents
O. V. Zhukova, O. V. Ruina, M. V. Khazov, S. V. Romanov
"... of moderate CAP were: 10.5 days and 731.65 rubles for ceftriaxone;  9.1 days and 1353.00 rubles ..."
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... перампанела предполагалось повышение стоимости лекарств (в млн руб.) на 15,2 (1,2%); 76,1 (6,2%); 152,4 (12 ..."
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... by 120 million rubles over 5 years. The sensitivity analysis shows the results are robust ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET Abstract  similar documents
R. I. Yagudina, V. G. Serpik
"... was 20,709 rubles. (Taking into account the costs of dialysis treatments), and for standard therapy - 110 ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... with sorafenib or lenvatinib was 7 285 716.92 rubles or 3 368 077.62 rubles, respectively. ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... with vector-borne infectious diseases comprised 909 million rubles in prices of 2011; most of the value ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... in patient survival. The total costs for belimumab vs standard therapy approximated 8.84 million rubles vs 17 ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... with the severity of the injury 31 points and made 11 000 and 5600 rubles. respectively. The cost of treating ..."
 
Vol 12, No 2 (2019) Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers Abstract  similar documents
E. V. Radchenko, A. S. Kolbin
"... disability) was 510.6 billion rubles. The difference between the smokers and the equal-sized non-smoking ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... % and 7% for the first, second and third year is expected to result in cost savings of 26.4 million rubles ..."
 
Vol 8, No 2 (2015) CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER Abstract  similar documents
Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov
"... of treatment five subclavian catheters necessary to spend 227.25 mln. rubles. And the implantations of venous ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... at the same time constitute 5 213 900 000 rub. (670.5 to 1184.3 million rubles per year). Calculated unit ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... of one patient annual therapy by 2.68 mln. rubles. Budget impact analysis evidences that Eltrombopag ..."
 
Vol 11, No 2 (2018) Clinical and economic efficiency of the loop ileostomy closure by various methods Abstract  similar documents
A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov
"... ,704.90 rubles. and 145,473.70 rubles, respectively, while in group 3, the cost was higher – 167,443,60 rubles (p ..."
 
Vol 8, No 4 (2015) PLANNING OF EXTENT AND FINANCIAL EXPENSES FOR DELIVERY OF HEALTH CARE IN HOSPITALS AT THE FEDERAL AND REGIONAL LEVELS Abstract  similar documents
M. V. Sura
"... per year; the norm of financial expenses was 63 743,8 rubles and 22 233,1 rubles per one case ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... ,878.21 rubles, and the cost of one additionally saved QALY – 365,060.31 rubles. Conclusion. The WTPT ..."
 
Vol 7, No 3 (2014) PROBLEMS OF OUTCOMES CHOICE FOR THE ASSESSMENT OF REHABILITATION PROGRAMS EFFICIENCY IN PATIENTS AFTER STROKE AND CRANIOCEREBRAL INJURY Abstract  similar documents
V. S. Dombrovskiy, V. V. Omelyanovskiy
"... критериев оценки программ реабилитации больных, перенесших инсульт, черепноозговую травму или другие ..."
 
Vol 10, No 2 (2017) ФАРМАКОЭКОНОМИЧЕСКАЯ ОЦЕНКА ПРИМЕНЕНИЯ ПОМАЛИДОМИДА (ИМНОВИД) ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ С РЕЦИДИВИРУЮЩЕЙ И РЕФРАКТЕРНОЙ МНОЖЕСТВЕННОЙ МИЕЛОМОЙ Abstract  similar documents
,
"... чувствительности. В результате было показано, что применение помалидомида для лечения больных с рецидивирующей и ..."
 
Vol 11, No 2 (2018) Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer Abstract  similar documents
G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin
"... лечение пациенток, больных раком молочной железы, при сохранении высоких показателей эффективности лечения ..."
 
Vol 5, No 1 (2012) COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko
"... , муковисцидозом, гипофизарным нанизмом, болезнью Гоше, мие- лолейкозом, рассеянным склерозом, а также после ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... ± ЛТ составил 5,8 млн руб., для ХТ ± ЛТ + аллоТСК vs ХТ ± ЛТ – 6,4 млн руб. Рассчитанная на втором ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... России, составит 2,838 млрд руб., 2,608 млрд руб. и 2,283 млрд руб. для монотерапии ЛС Эпртаког альфа ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... ) per a year of saved life with consideration of its quality comprised 1,097,078 rubles without ..."
 
Vol 10, No 3 (2017) Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis Abstract  similar documents
E. V. Biryukova, V. I. Ignat’eva
"... insulin for the model population of 1,000 patients was 22.5 million rubles. If the use of ready-made ..."
 
Vol 9, No 2 (2016) PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION Abstract  similar documents
T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva
"... льготными лекарственными препаратами больных хронической обструктивной болезнью легких (ХОБЛ) в Красноярском ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... пациентов использованы для оценки эффективности. Коэффициенты «затраты-эффективность» составили 440 759 руб ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... на лечение одного больного раком молочной железы с учетом схемы 6DAC составит 1 198 300 руб. и 1 371 ..."
 
Vol 8, No 4 (2015) HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS Abstract  similar documents
N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova
"... healthcare spending inefficient, which equals to real 269-435 billion rubles of inefficient spending annually.  ..."
 
1 - 50 of 154 Items 1 2 3 4 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)